These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 32731576)
21. Benzylideneoxymorphone: A new lead for development of bifunctional mu/delta opioid receptor ligands. Healy JR; Bezawada P; Griggs NW; Devereaux AL; Matsumoto RR; Traynor JR; Coop A; Cunningham CW Bioorg Med Chem Lett; 2017 Feb; 27(3):666-669. PubMed ID: 28011222 [TBL] [Abstract][Full Text] [Related]
22. Mechanistic Understanding of Peptide Analogues, DALDA, [Dmt Dumitrascuta M; Bermudez M; Ballet S; Wolber G; Spetea M Molecules; 2020 Apr; 25(9):. PubMed ID: 32365707 [TBL] [Abstract][Full Text] [Related]
23. Structure-activity relationships of dermorphin analogues containing N-substituted amino acids in the 2-position of the peptide sequence. Schmidt R; Kálmán A; Chung NN; Lemieux C; Horváth C; Schiller PW Int J Pept Protein Res; 1995 Jul; 46(1):47-55. PubMed ID: 7558596 [TBL] [Abstract][Full Text] [Related]
24. The importance of micelle-bound states for the bioactivities of bifunctional peptide derivatives for delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists. Yamamoto T; Nair P; Jacobsen NE; Davis P; Ma SW; Navratilova E; Moye S; Lai J; Yamamura HI; Vanderah TW; Porreca F; Hruby VJ J Med Chem; 2008 Oct; 51(20):6334-47. PubMed ID: 18821747 [TBL] [Abstract][Full Text] [Related]
25. Synthesis, Pharmacology, and Molecular Docking Studies on 6-Desoxo-N-methylmorphinans as Potent μ-Opioid Receptor Agonists. Dumitrascuta M; Ben Haddou T; Guerrieri E; Noha SM; Schläfer L; Schmidhammer H; Spetea M J Med Chem; 2017 Nov; 60(22):9407-9412. PubMed ID: 29053268 [TBL] [Abstract][Full Text] [Related]
26. The benzomorphan-based LP1 ligand is a suitable MOR/DOR agonist for chronic pain treatment. Pasquinucci L; Parenti C; Turnaturi R; Aricò G; Marrazzo A; Prezzavento O; Ronsisvalle S; Georgoussi Z; Fourla DD; Scoto GM; Ronsisvalle G Life Sci; 2012 Jan; 90(1-2):66-70. PubMed ID: 22100511 [TBL] [Abstract][Full Text] [Related]
28. Pharmacological characterization of orphanin FQ/nociceptin and its fragments. Rossi GC; Leventhal L; Bolan E; Pasternak GW J Pharmacol Exp Ther; 1997 Aug; 282(2):858-65. PubMed ID: 9262352 [TBL] [Abstract][Full Text] [Related]
29. Antinociceptive profile of LP1, a non-peptide multitarget opioid ligand. Parenti C; Turnaturi R; Aricò G; Marrazzo A; Prezzavento O; Ronsisvalle S; Scoto GM; Ronsisvalle G; Pasquinucci L Life Sci; 2012 Jun; 90(25-26):957-61. PubMed ID: 22580287 [TBL] [Abstract][Full Text] [Related]
30. Synthesis and pharmacological properties of a new fluorescent opioid peptide analog. Lukowiak M; Kosson P; Hennink WE; Lipkowski AW Pharmacol Rep; 2009; 61(4):727-31. PubMed ID: 19815956 [TBL] [Abstract][Full Text] [Related]
31. Novel Turnaturi R; Chiechio S; Pasquinucci L; Spoto S; Costanzo G; Dichiara M; Piana S; Grasso M; Amata E; Marrazzo A; Parenti C Molecules; 2022 Aug; 27(16):. PubMed ID: 36014375 [TBL] [Abstract][Full Text] [Related]
32. Discovery of potentially biased agonists of mu-opioid receptor (MOR) through molecular docking, pharmacophore modeling, and MD simulation. Jiang X; Li S; Zhang H; Wang LL Comput Biol Chem; 2021 Feb; 90():107405. PubMed ID: 33184004 [TBL] [Abstract][Full Text] [Related]
33. Pharmacological Comparison of Mitragynine and 7-Hydroxymitragynine: In Vitro Affinity and Efficacy for Obeng S; Wilkerson JL; León F; Reeves ME; Restrepo LF; Gamez-Jimenez LR; Patel A; Pennington AE; Taylor VA; Ho NP; Braun T; Fortner JD; Crowley ML; Williamson MR; Pallares VLC; Mottinelli M; Lopera-Londoño C; McCurdy CR; McMahon LR; Hiranita T J Pharmacol Exp Ther; 2021 Mar; 376(3):410-427. PubMed ID: 33384303 [TBL] [Abstract][Full Text] [Related]
34. Replacement of current opioid drugs focusing on MOR-related strategies. Busserolles J; Lolignier S; Kerckhove N; Bertin C; Authier N; Eschalier A Pharmacol Ther; 2020 Jun; 210():107519. PubMed ID: 32165137 [TBL] [Abstract][Full Text] [Related]
35. 14-O-Methylmorphine: A Novel Selective Mu-Opioid Receptor Agonist with High Efficacy and Affinity. Zádor F; Balogh M; Váradi A; Zádori ZS; Király K; Szűcs E; Varga B; Lázár B; Hosztafi S; Riba P; Benyhe S; Fürst S; Al-Khrasani M Eur J Pharmacol; 2017 Nov; 814():264-273. PubMed ID: 28864212 [TBL] [Abstract][Full Text] [Related]
36. Effect of a 6-cyano substituent in 14-oxygenated N-methylmorphinans on opioid receptor binding and antinociceptive potency. Spetea M; Greiner E; Aceto MD; Harris LS; Coop A; Schmidhammer H J Med Chem; 2005 Jul; 48(15):5052-5. PubMed ID: 16033285 [TBL] [Abstract][Full Text] [Related]
37. Design of a high affinity peptidomimetic opioid agonist from peptide pharmacophore models. Wang C; McFadyen IJ; Traynor JR; Mosberg HI Bioorg Med Chem Lett; 1998 Oct; 8(19):2685-8. PubMed ID: 9873603 [TBL] [Abstract][Full Text] [Related]
38. Discovery of a potent and efficacious peptide derivative for δ/μ opioid agonist/neurokinin 1 antagonist activity with a 2',6'-dimethyl-L-tyrosine: in vitro, in vivo, and NMR-based structural studies. Yamamoto T; Nair P; Largent-Milnes TM; Jacobsen NE; Davis P; Ma SW; Yamamura HI; Vanderah TW; Porreca F; Lai J; Hruby VJ J Med Chem; 2011 Apr; 54(7):2029-38. PubMed ID: 21366266 [TBL] [Abstract][Full Text] [Related]
40. Antinociceptive effects of the 6-O-sulfate ester of morphine in normal and diabetic rats: Comparative role of mu- and delta-opioid receptors. Yadlapalli JSK; Ford BM; Ketkar A; Wan A; Penthala NR; Eoff RL; Prather PL; Dobretsov M; Crooks PA Pharmacol Res; 2016 Nov; 113(Pt A):335-347. PubMed ID: 27637375 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]